DelveInsight’s ‘Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of TNBC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Triple Negative Breast Cancer (TNBC) from 2016 to 2027 segmented by G8 markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

1. Triple Negative Breast
Cancer (TNBC) – Market
Insight Epidemiology
and Market Forecast
Delveinsight © 2018 | All rights reserved

2. Introduction
Triple Negative Breast
Cancer (TNBC) is
defined as the
heterogeneous breast
cancer phenotype
where the estrogen
and progesterone
receptor are negative.
TNBCs are frequently
identified as hyper
dense masses without
associated calcifications.
The majority of TNBCs
are histologically
classified as high-grade,
invasive, ductal
carcinomas of no special
type with basal-like
features.
TNBC is characterized
by various aggressive
clinic pathologic
features including
onset at a younger
age, higher mean
tumor size, higher-
grade tumors, and a
higher rate of node
positivity
Delveinsight © 2018 | All rights reserved

3. Rest of
the World
US Market
Share
Key Findings
-50
0
50
100
150
200
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Ch
JP
UK
ESP
IT
FR
DE
US
MARKET SHARE
PREVALENCE 2016-2027
Delveinsight © 2018 | All rights reserved

4. Market Size
01
02
03
04
05
Market Size of Triple
Negative Breast
Cancer in the G8
Countries was found
to be XX in 2016
Owing to the launch of
upcoming therapies, the
market size shall increase
during forecast period
(2018-2027)
The market size is
expected to increase at
a CAGR of 18.9%
during the study
period
Expected launch of
Sacituzumab Govitecan
in US and EU5 for
treating Metastatic TNBC
cases shall fuel the
growth of the market
Sacituzumab
Govitecan is the only
antibody-based
product candidate will
give an edge to its sales
as it is a targeted
therapy
Delveinsight © 2018 | All rights reserved

5. Sacituzumab Govitecan Atezolizumab
Pembrolizumab
Emerging Drugs and Companies
Rucaparib
Niraparib Capivasertib
Delveinsight © 2018 | All rights reserved

6. Complete Information
For Complete Information please Click below
Or
Write us at
info@delveinsight.com
Click here
Delveinsight © 2018 | All rights reserved

7. Delveinsight
VISION
To be the most trusted
marketing research firm &
business consulting firm
world wide. To be a
renowned and premier
data driven solution
providers among Pharma
& Biotech companies
MISSION
“insight across the value
chain” to help
organizations make
important business
decisions through the use
and analysis of actionable
market intelligence
DELVEINSIGHT
DelveInsight, market
research and consulting
firm, provides end to end
comprehensive solutions to
the Life Science Industry
We help our customers in
best decision making
through our expertise in
research & analysis and
comes out with unmatched
data & forecasts
Delveinsight © 2018 | All rights reserved

8. Market
Intelligence
Forecasting
Opportunity
Assessment
Report Store
Socialytics
Competitive
Analysis
Consulting
Pipeline
Services Offered By Delveinsight
Delveinsight © 2018 | All rights reserved

9. Contact Us
info@delveinsight.com
+91-11-4568 9769
www.delveinsight.com
blog/delveInsight
twitter/delveInsight
LinkedIn/delveInsight
Delveinsight © 2018 | All rights reserved

10. Delveinsight © 2018 | All rights reserved